Cargando…

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review

BACKGROUND: Patients with breast cancer who overexpress the human epidermal growth factor receptor 2 (HER2) and subsequently develop brain metastasis (BM) typically experience poor quality of life and low survival. We conducted a comprehensive literature review to identify prognostic factors for BM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hackshaw, Michelle D., Danysh, Heather E., Henderson, Mackenzie, Wang, Eric, Tu, Nora, Islam, Zahidul, Ladner, Amy, Ritchey, Mary E., Salas, Maribel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403419/ https://www.ncbi.nlm.nih.gov/pubmed/34454469 http://dx.doi.org/10.1186/s12885-021-08708-5

Ejemplares similares

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
por: Hackshaw, Michelle D., et al.
Publicado: (2020)

Health-related quality of life in women with breast cancer: a review of measures
por: Salas, Maribel, et al.
Publicado: (2022)

Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review
por: Salas, Maribel, et al.
Publicado: (2021)

Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers
por: Salas, Maribel, et al.
Publicado: (2020)

Discrepancies in ICD-9/ICD-10-based codes used to identify three common diseases in cancer patients in real-world settings and their implications for disease classification in breast cancer patients and patients without cancer: a literature review and descriptive study
por: Tu, Nora, et al.
Publicado: (2023)

Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study
por: Mansfield, Carol, et al.
Publicado: (2022)

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer
por: Pranjol, Md Zahidul Islam, et al.
Publicado: (2015)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
por: Yang, Ziyan, et al.
Publicado: (2020)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China
por: Qin, Tao, et al.
Publicado: (2015)

Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis
por: Tong, Zhen-Jun, et al.
Publicado: (2017)

Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
por: Palm, Christiane, et al.
Publicado: (2023)

Association of traffic-related hazardous air pollutants and cervical dysplasia in an urban multiethnic population: a cross-sectional study
por: Scheurer, Michael E, et al.
Publicado: (2014)

Role of HER2 in local relapse and metastasis
por: Ménard, S
Publicado: (2005)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Prognostic value HER-2/neu expression in T1 to T3 breast cancer with axillary lymph node metastasis
por: Maksimovic, S
Publicado: (2009)

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma
por: Tie, Xiaowei, et al.
Publicado: (2022)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer
por: Smith, Daniel L., et al.
Publicado: (2021)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer
por: Dent, Susan F., et al.
Publicado: (2022)

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
por: Liu, Yi, et al.
Publicado: (2013)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer
por: Karadag, Ibrahim, et al.
Publicado: (2023)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone
por: Zhang, Lei, et al.
Publicado: (2021)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Maternal Residential Proximity to Major Roadways and Pediatric Embryonal Tumors in Offspring
por: Kumar, Shwetha V., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j8h0f8ql3oit7lmfqa87sjo2uc